Spyre Therapeutics Announces Grants of Inducement Awards

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock option awards to two non-executive employees under the Spyre 2018 Equity Inducement Plan.

The awards total 20,300 options, were approved on December 1, 2025, have a 10-year term, and an exercise price of $28.66 (Nasdaq closing price on December 1, 2025). Vesting is one-quarter on the first anniversary of each employee’s start date and then 1/48th monthly thereafter, subject to continuous service; the options are subject to the 2018 Plan and were described as material to each employee’s acceptance under Nasdaq Listing Rule 5635(c)(4).

Key Figures

Inducement options granted 20,300 shares Stock options to two non-executive employees under 2018 Plan

Number of employees 2 employees Recipients of inducement stock option grants

Exercise price $28.66 Exercise price equal to Nasdaq closing price on Dec 1, 2025

Option term 10 years Term of inducement stock options granted Dec 1, 2025

Initial vesting 1/4 of shares Vests on first anniversary of employee’s start date

Ongoing vesting 1/48 monthly Remaining shares vest monthly thereafter, subject to service

Current share price $33.55 Price before this inducement awards news

20-day avg volume 643,713 shares Average daily volume over prior 20 trading days

Market Reality Check

$33.55 Last Close

Volume Volume 767,231 is 19% above the 20-day average of 643,713. normal

Technical Shares at $33.55 are trading above the 200-day MA of $17.80 and 2.87% below the 52-week high.

Peers on Argus

SYRE gained 4.19% with modestly mixed peer moves: UPB +5.1%, RAPP +3.01%, ABUS slightly positive, while URGN and VERV were slightly negative. Two peers (RAPP, URGN) also reported news, including a similar inducement‑grant announcement at URGN, suggesting company‑specific rather than broad sector momentum.

Common Catalyst Multiple biotech peers issued routine corporate updates, including inducement equity grants and clinical data releases.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 07	Inducement awards	Neutral	-1.5%	Inducement stock options for 19,600 shares to a new employee.
Nov 04	Earnings and update	Positive	-0.6%	Q3 results, positive Phase 1 data, major financing and cash runway update.
Nov 04	Clinical trial data	Positive	-0.6%	Positive interim Phase 1 results for SPY003 in 59 healthy volunteers.
Oct 29	Conference participation	Positive	+1.8%	Announcement of participation in three November healthcare investor conferences.
Oct 24	Poster presentations	Positive	+4.5%	Positive SPY072 Phase 1 and preclinical data presented at ACR 2025.

Pattern Detected

Positive clinical and corporate updates have produced mixed short-term reactions, with both gains and pullbacks, while prior inducement grants drew a modest decline.

Recent Company History

Over the past few months, Spyre reported several milestones, including positive interim Phase 1 data for SPY003 and SPY072, an underwritten equity offering with gross proceeds of $316M+, and Q3 2025 results highlighting a strong cash position. News tied to clinical progress and conferences on Oct 24 and Oct 29 saw positive moves, while earnings and clinical updates on Nov 4 coincided with small declines. A prior inducement grant on Nov 7 also saw a slight negative reaction, framing today’s awards as consistent with ongoing hiring and equity compensation use.

Market Pulse Summary

This announcement details inducement stock options for 20,300 shares granted to two non-executive employees at an exercise price of $28.66 and a 10-year term, vesting over four years. It follows a prior inducement grant on Nov 7, 2025 and sits alongside recent clinical and financing milestones. Investors may track ongoing use of equity compensation, future trial readouts, and subsequent SEC filings to understand how hiring and pipeline expansion interact with Spyre’s capital structure.

Key Terms

antibodies medical

"pioneering long-acting antibodies and antibody combinations to redefine the standard"

Antibodies are proteins made by the body’s immune system that recognize and bind to specific foreign substances, like virus or bacteria pieces, much like a lock matched to a key. For investors, antibodies matter because they are the basis for diagnostic tests, vaccines and many therapies — changes in antibody data or the success of antibody-based products can directly affect a healthcare company’s revenue prospects and perceived value.

equity inducement awards financial

"as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

Nasdaq Listing Rule 5635(c)(4) regulatory

"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"a 10-year term and an exercise price equal to $28.66, the closing price per"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"options granted to the employees shall vest and become exercisable as to one-fourth"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,300 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on December 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $28.66, the closing price per share of Spyre's common stock as reported by Nasdaq on December 1, 2025. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

For Investors :
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

What inducement awards did Spyre Therapeutics (SYRE) grant on December 1, 2025?

Spyre granted an aggregate of 20,300 stock options to two non-executive employees as inducement awards approved on December 1, 2025.

What is the exercise price and term of the SYRE inducement stock options?

Each option has a 10-year term and an exercise price of $28.66, the Nasdaq closing price on December 1, 2025.

How do the inducement options for SYRE vest for new employees?

Vesting is 25% on the first anniversary of each employee’s start date and then 1/48th of the shares monthly thereafter, subject to continuous service.

Why were the SYRE stock options described as material to employees?

The company stated the stock options were material to each employee's acceptance of employment, consistent with Nasdaq Listing Rule 5635(c)(4).

Under which plan were the Spyre inducement awards granted?

The options were granted under the Spyre Therapeutics 2018 Equity Inducement Plan, as amended.